GO:0047865 dimethylglycine dehydrogenase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0047865 defines dimethylglycine dehydrogenase (DMGDH) activity, which catalyzes the oxidative demethylation of N,N-dimethylglycine to sarcosine and formaldehyde, transferring electrons to electron-transfer flavoprotein.
• DMGDH is a mitochondrial matrix enzyme that requires covalently bound FAD and is part of the choline degradation pathway, linking choline metabolism to one-carbon metabolism.
• The human DMGDH gene is located on chromosome 5q14.1 and encodes a precursor protein that is imported into mitochondria.
• Pathogenic variants in DMGDH, such as H109R, cause dimethylglycine dehydrogenase deficiency, an inborn error of choline metabolism characterized by elevated dimethylglycine in body fluids.
• DMGDH activity is important in liver, kidney, and other tissues, and its dysfunction has been linked to metabolic and neurological abnormalities.
• Research on DMGDH utilizes knockout models, enzyme assays, and metabolomics to dissect its role in choline catabolism and disease.
Description
Dimethylglycine dehydrogenase (DMGDH) activity, encoded by the GO term GO:0047865, is a mitochondrial enzyme that catalyzes the oxidative demethylation of N,N-dimethylglycine (DMG) to sarcosine (N-methylglycine) and formaldehyde, while reducing electron-transfer flavoprotein (ETF). This reaction is a key step in the choline degradation pathway, which is essential for maintaining cellular one-carbon metabolism and methyl group homeostasis. DMGDH is a flavoprotein that contains covalently bound flavin adenine dinucleotide (FAD) and is localized in the mitochondrial matrix. The enzyme is highly expressed in liver and kidney, where it contributes to the metabolism of choline and glycine betaine. Dysregulation of DMGDH activity has been associated with metabolic disorders and neurological conditions. For example, mutations in the DMGDH gene cause dimethylglycine dehydrogenase deficiency, an inborn error of metabolism characterized by elevated levels of DMG in blood and urine, and variable clinical presentations including muscle weakness and developmental delay. Additionally, DMGDH has been implicated in the metabolism of glycine betaine in bacteria, highlighting its evolutionary conservation. Understanding the molecular mechanism and regulation of DMGDH is therefore important for both basic biochemistry and clinical research. Recent studies have explored the role of DMGDH in various physiological and pathological contexts, including its potential involvement in inflammatory pathways and metabolic reprogramming. The enzyme's dependence on electron-transfer flavoprotein links it to mitochondrial energy metabolism and oxidative phosphorylation. This article provides a comprehensive overview of GO:0047865, covering its definition, mechanism, key genes, disease associations, and research methodologies, with a focus on CRISPR-based models for functional studies.
dimethylglycine dehydrogenase activity At A Glance
| GO ID | GO:0047865 |
|---|---|
| GO term | dimethylglycine dehydrogenase activity |
| Ontology | molecular_function |
| Synonym | N,N-dimethylglycine:(acceptor) oxidoreductase (demethylating); N,N-dimethylglycine:acceptor oxidoreductase (demethylating); N,N-dimethylglycine oxidase activity |
| Major function | Catalyzes the oxidative demethylation of N,N-dimethylglycine to sarcosine and formaldehyde, using electron-transfer flavoprotein as an electron acceptor. |
| Cofactor | Covalently bound FAD (flavin adenine dinucleotide) |
| Subcellular location | Mitochondrial matrix |
| Pathway | Choline degradation / glycine betaine metabolism |
| Reaction | N,N-dimethylglycine + electron-transfer flavoprotein + H2O = sarcosine + formaldehyde + reduced electron-transfer flavoprotein |
What Is GO:0047865?
GO:0047865, dimethylglycine dehydrogenase activity, is defined as the catalysis of the reaction: N,N-dimethylglycine + electron-transfer flavoprotein + H2O = sarcosine + formaldehyde + reduced electron-transfer flavoprotein. In other words, it is the enzyme activity that removes a methyl group from dimethylglycine, producing sarcosine and formaldehyde, while transferring electrons to the electron-transfer flavoprotein (ETF). This activity is synonymous with N,N-dimethylglycine:(acceptor) oxidoreductase (demethylating), N,N-dimethylglycine:acceptor oxidoreductase (demethylating), and N,N-dimethylglycine oxidase activity.
Why Is dimethylglycine dehydrogenase activity Important in Cell Biology?
DMGDH activity is critical for choline metabolism and one-carbon homeostasis, impacting methylation reactions, mitochondrial energy production, and cellular detoxification of formaldehyde. Its dysfunction leads to dimethylglycine dehydrogenase deficiency, a rare metabolic disorder with neurological and muscular symptoms. Moreover, DMGDH is conserved across species, from mammals to bacteria, underscoring its fundamental biochemical role. Research into DMGDH provides insights into metabolic diseases, mitochondrial biology, and potential therapeutic targets.
• DMGDH is a key enzyme in the choline degradation pathway, converting dimethylglycine to sarcosine and feeding into one-carbon metabolism.
• Deficiency in DMGDH activity causes dimethylglycine dehydrogenase deficiency, characterized by elevated dimethylglycine and variable clinical symptoms.
• The enzyme requires electron-transfer flavoprotein (ETF), linking its activity to mitochondrial electron transport and energy metabolism.
• DMGDH is expressed in liver and kidney, where it plays a role in detoxification and methyl group balance.
• Genetic variants in DMGDH, such as H109R, have been structurally and functionally characterized, providing insights into enzyme mechanism.
• DMGDH activity is relevant to bacterial metabolism, as shown in Methylorubrum extorquens, where alterations enable glycine betaine metabolism.
• The enzyme's product, sarcosine, is a metabolite of interest in cancer and neurological research.
• DMGDH may interact with inflammatory pathways, as suggested by studies on herbal medicines affecting metabolism.
• Toxicological studies on Xanthium strumarium highlight the importance of choline metabolism enzymes in hepatotoxicity.
• DMGDH serves as a model for flavoprotein chemistry and mitochondrial import studies.
Molecular Mechanism of dimethylglycine dehydrogenase activity
Substrate Binding and Catalysis
In simple terms: The enzyme grabs dimethylglycine and removes a methyl group, producing sarcosine and formaldehyde.
DMGDH binds N,N-dimethylglycine (DMG) in its active site, where a covalent FAD cofactor facilitates the oxidative demethylation reaction. The enzyme transfers electrons from DMG to electron-transfer flavoprotein (ETF), generating reduced ETF, while the methyl group is released as formaldehyde, yielding sarcosine. This reaction is stereospecific and requires water as a co-substrate.
Cofactor and Electron Transfer
In simple terms: A built-in FAD molecule helps move electrons to another protein, ETF.
DMGDH contains covalently bound FAD, which is essential for its catalytic activity. The FAD cofactor accepts electrons from the substrate and transfers them to ETF, a soluble electron carrier in the mitochondrial matrix. This electron transfer links DMGDH activity to the respiratory chain via ETF-ubiquinone oxidoreductase.
Mitochondrial Import and Processing
In simple terms: The enzyme is made in the cytoplasm and then moved into mitochondria, where it works.
The human DMGDH gene encodes a precursor protein with a mitochondrial targeting sequence that directs it to the mitochondrial matrix. After import, the targeting sequence is cleaved, and the mature enzyme folds with its FAD cofactor. The mitochondrial localization ensures access to DMG and ETF.
Regulation of DMGDH Activity
In simple terms: The enzyme's activity can be turned up or down by cellular conditions and gene expression.
DMGDH activity is regulated at the transcriptional level, with expression influenced by nutritional and hormonal signals. The enzyme's activity may also be modulated by substrate availability and the redox state of the mitochondrial matrix. Additionally, mutations in the DMGDH gene can impair enzyme function, as seen in H109R variant.
Key Genes Involved in GO:0047865 dimethylglycine dehydrogenase activity
The following genes and proteins are directly involved in dimethylglycine dehydrogenase activity or its metabolic context.
| Gene | Major Role | Research Relevance |
|---|---|---|
| DMGDH | Encodes dimethylglycine dehydrogenase, the enzyme catalyzing the reaction | Mutations cause DMGDH deficiency; target for metabolic studies |
| ETFA | Encodes electron-transfer flavoprotein alpha subunit, accepts electrons from DMGDH | Required for DMGDH activity; mutations cause glutaric acidemia type II |
| ETFB | Encodes electron-transfer flavoprotein beta subunit, part of ETF complex | Interacts with DMGDH for electron transfer |
| ETFDH | Encodes ETF-ubiquinone oxidoreductase, links ETF to respiratory chain | Downstream of DMGDH in electron transfer |
| SARDH | Encodes sarcosine dehydrogenase, converts sarcosine to glycine | Next step in choline degradation pathway |
| GLDC | Encodes glycine decarboxylase, involved in glycine cleavage system | Related to one-carbon metabolism |
| AMT | Encodes aminomethyltransferase, part of glycine cleavage system | Links to folate metabolism |
| MTHFD1 | Encodes methylenetetrahydrofolate dehydrogenase, one-carbon metabolism | Affects methylation potential |
| BHMT | Encodes betaine-homocysteine S-methyltransferase, converts betaine to DMG | Upstream of DMGDH in choline pathway |
| CHDH | Encodes choline dehydrogenase, oxidizes choline to betaine aldehyde | Upstream of DMGDH |
| PEMT | Encodes phosphatidylethanolamine N-methyltransferase, synthesizes phosphatidylcholine | Competes with choline oxidation |
| MAT1A | Encodes methionine adenosyltransferase, produces SAM | Affected by one-carbon flux |
| GNMT | Encodes glycine N-methyltransferase, regulates SAM/SAH ratio | Linked to methylation homeostasis |
| AHCY | Encodes S-adenosylhomocysteine hydrolase, controls SAH levels | Affects methylation reactions |
| CBS | Encodes cystathionine beta-synthase, transsulfuration pathway | Connects to homocysteine metabolism |
| MTR | Encodes methionine synthase, regenerates methionine | Folate and B12 dependent |
| MTHFR | Encodes methylenetetrahydrofolate reductase, folate metabolism | Impacts one-carbon supply |
| SHMT1 | Encodes serine hydroxymethyltransferase, one-carbon metabolism | Provides methyl groups |
How Is dimethylglycine dehydrogenase activity Regulated?
DMGDH activity is primarily regulated by gene expression and substrate availability. The DMGDH promoter contains response elements that may respond to hormonal and nutritional signals. Additionally, the enzyme's activity depends on the availability of its substrates, dimethylglycine and electron-transfer flavoprotein, and on the mitochondrial redox state. Post-translational modifications have not been extensively characterized, but the enzyme's covalent FAD is essential for catalysis. Inborn mutations, such as H109R, can drastically reduce activity, leading to metabolic imbalance.
dimethylglycine dehydrogenase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| DMGDH | Dimethylglycine dehydrogenase deficiency | Knockout mouse or patient-derived fibroblasts |
| DMGDH | Hyperdimethylglycinemia | Point mutation knock-in (e.g., H109R) in cell lines |
| ETFA/ETFB | Glutaric acidemia type II | Knockout cell models to study electron transfer |
| SARDH | Sarcosinemia | Overexpression and knockout models |
| BHMT | Hyperhomocysteinemia | Knockout mice and liver cells |
Dimethylglycine Dehydrogenase Deficiency
Dimethylglycine dehydrogenase deficiency is an autosomal recessive inborn error of metabolism caused by mutations in the DMGDH gene. Patients exhibit elevated levels of dimethylglycine in blood and urine, and may present with muscle weakness, developmental delay, and neurological symptoms. The H109R variant has been structurally characterized, showing impaired FAD binding and reduced catalytic activity.
Metabolic and Neurological Associations
Altered DMGDH activity has been linked to disturbances in one-carbon metabolism, which can affect methylation reactions and neurotransmitter synthesis. Folate deficiency, which impacts methylation, may interact with DMGDH dysfunction. Additionally, studies on herbal medicines and toxins suggest that DMGDH may be involved in inflammatory and hepatotoxic pathways.
Cancer and Sarcosine Metabolism
Sarcosine, the product of DMGDH, has been implicated in cancer progression, particularly prostate cancer, where elevated sarcosine levels are associated with aggressive disease. Although direct DMGDH mutations are not common in cancer, altered choline metabolism may influence sarcosine availability.
From dimethylglycine dehydrogenase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does DMGDH loss affect choline metabolism? | DMGDH knockout cell line (e.g., HepG2) |
| What is the effect of the H109R mutation on enzyme activity? | Point mutation knock-in (H109R) in HEK293 cells |
| Can DMGDH be tagged for localization studies? | Knock-in of FLAG or GFP tag at endogenous locus |
| Does DMGDH overexpression alter sarcosine levels? | Overexpression in liver cell lines |
| What are the metabolic consequences of DMGDH deficiency? | Patient-derived induced pluripotent stem cells |
| How does DMGDH interact with ETF? | Co-immunoprecipitation in knockout background |
How to Study the dimethylglycine dehydrogenase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Enzyme activity assay | DMGDH catalytic rate | Kinetic studies and inhibitor testing |
| Western blot | DMGDH protein levels | Expression analysis in tissues |
| qRT-PCR | DMGDH mRNA expression | Transcriptional regulation studies |
| Metabolomics (LC-MS) | Dimethylglycine, sarcosine, formaldehyde | Metabolic profiling in cells and fluids |
| CRISPR knockout | Loss of DMGDH function | Phenotypic screens and disease models |
| Site-directed mutagenesis | Effect of point mutations | Structure-function analysis |
| Immunofluorescence | Subcellular localization | Mitochondrial import studies |
| Co-immunoprecipitation | Protein-protein interactions | ETF binding studies |
Enzymatic Activity Assays
DMGDH activity can be measured spectrophotometrically by monitoring the reduction of electron-transfer flavoprotein (ETF) at 420 nm or by coupling to a dye such as dichlorophenolindophenol. These assays use purified enzyme or mitochondrial extracts and require dimethylglycine as substrate.
Metabolomics and Flux Analysis
Metabolomic profiling by mass spectrometry can quantify dimethylglycine, sarcosine, and formaldehyde levels in cells or body fluids. Stable isotope tracing with deuterated dimethylglycine can reveal flux through the DMGDH reaction.
Genetic and CRISPR Screens
CRISPR knockout screens can identify genes required for DMGDH activity or choline metabolism. Targeted knockout of DMGDH in cell lines allows functional studies of its role in metabolism and disease.
Structural and Biophysical Methods
X-ray crystallography and cryo-EM can determine the structure of DMGDH and its variants, revealing substrate binding and FAD coordination. Circular dichroism and fluorescence spectroscopy assess folding and cofactor binding.
How CRISPR Can Be Used to Study GO:0047865 dimethylglycine dehydrogenase activity
Knockout
CRISPR-Cas9 knockout of DMGDH in cell lines such as HepG2 or HEK293 can abolish enzyme activity, leading to accumulation of dimethylglycine and reduced sarcosine. These models are useful for studying metabolic consequences and compensatory pathways.
Point Mutation
Knock-in of specific DMGDH mutations, such as H109R, using CRISPR homology-directed repair allows precise modeling of patient variants. These models help dissect the molecular basis of enzyme deficiency and test therapeutic strategies.
Knock-in
Tagging endogenous DMGDH with fluorescent or affinity tags via CRISPR knock-in enables real-time localization and interaction studies. This approach preserves endogenous regulation and avoids overexpression artifacts.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of DMGDH can increase enzyme levels, useful for studying flux through the choline degradation pathway and its impact on methylation.
How EDITGENE Supports dimethylglycine dehydrogenase activity Research
Researchers studying dimethylglycine dehydrogenase activity-related genes often need to determine whether a candidate gene is causally involved in metabolic pathways or disease phenotypes. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell models, enabling functional validation of DMGDH and related genes.
Contact EDITGENE today to design your custom CRISPR model for dimethylglycine dehydrogenase activity research.
Frequently Asked Questions About dimethylglycine dehydrogenase activity
What is dimethylglycine dehydrogenase activity?
Dimethylglycine dehydrogenase activity (GO:0047865) is the enzyme activity that catalyzes the conversion of N,N-dimethylglycine to sarcosine and formaldehyde, transferring electrons to electron-transfer flavoprotein.
What gene encodes dimethylglycine dehydrogenase?
The human DMGDH gene encodes dimethylglycine dehydrogenase.
What is the function of DMGDH in metabolism?
DMGDH functions in the choline degradation pathway, helping to break down dimethylglycine and produce sarcosine, which feeds into one-carbon metabolism.
What diseases are associated with DMGDH mutations?
Mutations in DMGDH cause dimethylglycine dehydrogenase deficiency, characterized by elevated dimethylglycine and neurological symptoms.
Where is DMGDH located in the cell?
DMGDH is localized in the mitochondrial matrix.
What cofactor does DMGDH require?
DMGDH requires covalently bound FAD (flavin adenine dinucleotide) for its activity.
How is DMGDH activity measured?
DMGDH activity can be measured spectrophotometrically by monitoring the reduction of electron-transfer flavoprotein or using coupled dye assays.
What is the reaction catalyzed by DMGDH?
The reaction is: N,N-dimethylglycine + electron-transfer flavoprotein + H2O = sarcosine + formaldehyde + reduced electron-transfer flavoprotein.
Are there animal models for DMGDH deficiency?
Yes, knockout mouse models and patient-derived cell lines are used to study DMGDH deficiency.
How can CRISPR be used to study DMGDH?
CRISPR can generate DMGDH knockout, point mutation knock-in, or tagged cell lines to study its function and disease relevance.
Conclusion
Dimethylglycine dehydrogenase activity (GO:0047865) is a fundamental enzymatic function in choline metabolism, with critical roles in one-carbon homeostasis and mitochondrial energy transfer. Its dysfunction leads to a rare metabolic disorder, and ongoing research continues to uncover its broader implications in health and disease. Advances in CRISPR-based models and metabolomics will further elucidate the molecular mechanisms and therapeutic potential of targeting DMGDH.
References
- 1. Porter DH et al.. 1985. Enzymatic properties of dimethylglycine dehydrogenase and sarcosine dehydrogenase from rat liver.. Arch Biochem Biophys 243(2):396-407 PMID: 2417560
- 2. Feng P et al.. 2025. Shiwei Longdanhua Capsule protects from hygrothermal condition and influenza infection by suppressing metabolism and inflammatory pathway.. Phytomedicine 148:157343 PMID: 41075514
- 3. Garcia BA et al.. 2016. Folate deficiency affects histone methylation.. Med Hypotheses 88:63-7 PMID: 26880641
- 4. Hying ZT et al.. 2024. Glycine betaine metabolism is enabled in Methylorubrum extorquens PA1 by alterations to dimethylglycine dehydrogenase.. Appl Environ Microbiol 90(7):e0209023 PMID: 38534142
- 5. Binzak BA et al.. 2000. Structure and analysis of the human dimethylglycine dehydrogenase gene.. Mol Genet Metab 69(3):181-7 PMID: 10767172
- 6. McAndrew RP et al.. 2008. Molecular basis of dimethylglycine dehydrogenase deficiency associated with pathogenic variant H109R.. J Inherit Metab Dis 31(6):761-8 PMID: 18937046
- 7. Xue LM et al.. 2014. Hepatotoxic constituents and toxicological mechanism of Xanthium strumarium L. fruits.. J Ethnopharmacol 152(2):272-82 PMID: 24447814
- 8. Parekh T et al.. 2024. Choline degradation in Paracoccus denitrificans: identification of sources of formaldehyde.. J Bacteriol 206(4):e0008124 PMID: 38501746
